Hepatitis Newswire (Page 8)

Hepatitis Newswire (Page 8)

Comprehensive Real-Time News Feed for Hepatitis. (Page 8)

Results 141 - 160 of 40,386 in Hepatitis

  1. Dynavax to Present at the William Blair 38th Annual Growth Stock ConferenceRead the original story

    Monday Jun 11 | Information Technology

    ... and develops novel vaccines and immuno-oncology therapeutics. The Company's first commercial product, HEPLISAV-BA [Hepatitis B Vaccine (Recombinant), Adjuvanted], was approved by the United States Food and Drug Administration in November 2017 for ...

    Comment?

  2. Immune system does not recover despite cured hepatitis C infectionRead the original story

    Monday Jun 11 | PressReleasePoint

    The findings, presented in Nature Communications, increases understanding about chronic infection and the way it regulates and impacts composition of the immune system. Infection with hepatitis C virus turns almost always chronic and poses a major health problem around the world.

    Comment?

  3. Vical's stock plunges 23% premarket after genital herpes treatment fails in phase 2 trialRead the original story w/Photo

    Monday Jun 11 | MarketWatch

    ... of patients with invasive aspergillosis; and early stage development program of a novel treatment for chronic hepatitis B virus (CHB) infection based on its DNA and lipid-delivery technologies. The company was founded by Howard E. Greene, Jr. ...

    Comment?

  4. Enanta Pharmaceuticals (ENTA) Now Covered by Analysts at OppenheimerRead the original story w/Photo

    Sunday Jun 10 | IntersportsWire

    ... nt of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary

    Comment?

  5. Nigeria:Nigeria, Others Account for Half of Child Deaths From Pneumonia, MeningitisRead the original story w/Photo

    Sunday Jun 10 | AllAfrica.com

    ... Pentavalent vaccine is a combination of five vaccines-in-one that prevents diphtheria, tetanus, whooping cough, hepatitis B and Hib, all through a single dose. According to the researchers led by Brian Wahl, Hib and Streptococcus pneumonia ...

    Comment?

  6. VBI Vaccines (VBIV) Receives $11.50 Consensus PT from BrokeragesRead the original story w/Photo

    Sunday Jun 10 | Daily Political

    ... disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a third-generation hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines ...

    Comment?

  7. Platform developed to deliver effective single-dose vaccines for multiple virusesRead the original story

    Sunday Jun 10 | Xinhuanet

    ... Malaria, all with major epidemic potential with high human lethality, as well as therapeutic vaccines for chronic hepatitis B infections and tumor-associated antigen-based cancer vaccines.

    Comment?

  8. Development of vaccines from AIDS to Zika, using a novel 'plug and play' viral platformRead the original story w/Photo

    Sunday Jun 10 | Science Blog

    ... Malaria, all with major epidemic potential with high human lethality, as well as therapeutic vaccines for chronic hepatitis B infections and tumor-associated antigen (TAA)-based-cancer vaccines. These studies on single-dose vaccines for emerging ...

    Comment?

  9. Biotech Bargains: Two Cheap Small-Cap Stocks in an Exciting SectorRead the original story

    Sunday Jun 10 | TheStreet.com

    ... are just a side show for the company at this point. Dynavax's main asset for the time being is Heplisav-B, a hepatitis B vaccine approved by the FDA late in 2017. The rollout is just getting traction, but the vaccine should see $300 million to $500 ...

    Comment?

  10. Dynavax Technologies (DVAX) Given Media Impact Rating of 0.11Read the original story w/Photo

    Sunday Jun 10 | Daily Political

    ... through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a ...

    Comment?

  11. Zacks: Analysts Expect Dicerna Pharmaceuticals Inc (DRNA) to Post -$0.42 EPSRead the original story w/Photo

    Sunday Jun 10 | The Breeze

    ... programs include DCR-PHXC for the treatment of primary hyperoxaluria; DCR-HBVS for the treatment of chronic hepatitis B virus infection; and DCR-PCSK9 to treat hypercholesterolemia. Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter ...

    Comment?

  12. CDC Report Shows MRSA Risk Associated With Injection Drug UseRead the original story

    Sunday Jun 10 | Pharmacy Times

    Individuals who inject drugs are at an increased risk of developing invasive methicillin-resistant Staphylococcus aureus . Alarmingly, opioid overdose death rates have increased by over 200% during 1999-2015.1 Heroin overdose death rates increased by about 300% during 2011-2015.1 Studies have consistently demonstrated the increased risk of HIV and hepatitis C infections.

    Comment?

  13. Acuta Capital Partners LLC Purchases Shares of 1,762,206 Arrowhead Pharmaceuticals IncRead the original story w/Photo

    Sunday Jun 10 | Daily Political

    ... of intractable diseases in the United States. Its pre-clinical stage medicines include ARO-HBV to treat chronic hepatitis B virus infection; ARO-AAT for the treatment of liver disease associated with alpha-1 antitrypsin deficiency; ARO-APOC3 and ...

    Comment?

  14. 19 Confirmed Cases of Hepatitis A in Lawrence CountyRead the original story

    Sunday Jun 10 | WBIW-AM Bedford

    The number of hepatitis A cases in Lawrence County increased by one, according to a weekly report from the Indiana State Department of Health. So far, in Indiana there are 124 confirmed cases of hepatitis A. There have been no deaths reported related to these cases.

    Comment?

  15. What do yellow toenails mean?Read the original story w/Photo

    Sunday Jun 10 | Medical News Today

    Excessive nail polish use or fungal infections are the most likely causes of yellow toenails. However, yellow toenails can sometimes be a sign of a more serious underlying condition.

    Comment?

  16. Enanta Pharmaceuticals (ENTA) Research Coverage Started at Roth CapitalRead the original story w/Photo

    Sunday Jun 10 | Daily Political

    ... of viral infections and liver diseases. The company's research and development focuses on disease targets: hepatitis B virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and respiratory syncytial virus. Receive News & Ratings ...

    Comment?

  17. Public urged to stay vigilant against water-borne diseasesRead the original story w/Photo

    Sunday Jun 10 | Manila Bulletin

    According to the Department of Health, water-borne diseases like typhoid fever, cholera, leptospirosis, and hepatitis are common during the rainy season due to flooding caused by typhoons or heavy rains. To ensure one's safety, the DOH has reminded the public to make sure that their drinking water should come from a safe source.

    Comment?

  18. Don't forget visas, vaccinations and the right travel insurance for your gap yearRead the original story w/Photo

    Sunday Jun 10 | This Is Money

    ... can be A 50 for each of the most common vaccinations for gap year travel, such as yellow fever, rabies and hepatitis B), it is not a risk worth taking. Macrae says: 'Backpackers can check the National Travel Health Network Centre website ...

    Comment?

  19. Brokerages Expect Assembly Biosciences Inc (ASMB) to Announce -$0.90 EPSRead the original story w/Photo

    Saturday Jun 9 | AmericanBankingNews.com

    ... operates as a clinical stage biotechnology company. It develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection and novel class of oral synthetic live biotherapeutic candidates to treat disorders associated with ...

    Comment?

  20. Cantor Fitzgerald Weighs in on Dynavax Technologies' FY2018 EarningsRead the original story w/Photo

    Saturday Jun 9 | IntersportsWire

    ... through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a ...

    Comment?